ATE417616T1 - Behandlung von mukositis - Google Patents
Behandlung von mukositisInfo
- Publication number
- ATE417616T1 ATE417616T1 AT03724064T AT03724064T ATE417616T1 AT E417616 T1 ATE417616 T1 AT E417616T1 AT 03724064 T AT03724064 T AT 03724064T AT 03724064 T AT03724064 T AT 03724064T AT E417616 T1 ATE417616 T1 AT E417616T1
- Authority
- AT
- Austria
- Prior art keywords
- mucositis
- treatment
- Prior art date
Links
- 206010028116 Mucosal inflammation Diseases 0.000 title 1
- 201000010927 Mucositis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38222502P | 2002-05-21 | 2002-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE417616T1 true ATE417616T1 (de) | 2009-01-15 |
Family
ID=29584378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03724064T ATE417616T1 (de) | 2002-05-21 | 2003-04-18 | Behandlung von mukositis |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20030236217A1 (de) |
| EP (1) | EP1509234B1 (de) |
| AR (1) | AR040036A1 (de) |
| AT (1) | ATE417616T1 (de) |
| AU (1) | AU2003230952A1 (de) |
| DE (1) | DE60325353D1 (de) |
| TW (1) | TW200402301A (de) |
| WO (1) | WO2003099297A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20040989A1 (it) | 2004-05-18 | 2004-08-18 | Gentium Spa | Uso del sulglicotide per iul trattamento delle mucositi |
| US20050276762A1 (en) * | 2004-06-15 | 2005-12-15 | Tapas Das | Topical compositions containing 5'-adenosine-diphosphate ribose |
| GB0501476D0 (en) * | 2005-01-25 | 2005-03-02 | Heptagen Ltd | Treatment for mucositis |
| US20070231274A1 (en) * | 2006-03-28 | 2007-10-04 | Myrex Pharmaceuticals Inc. | Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis |
| US20100190735A1 (en) * | 2006-03-28 | 2010-07-29 | Myrex Pharmaceuticals Inc. | Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis |
| AR058834A1 (es) * | 2006-11-06 | 2008-02-27 | Univ Nac Quilmes | Un compuesto con actividad inhibitoria de una proteina celular rho-gtpasa, un procedimiento para su obtencion, composiciones farmaceuticas que lo comprenden y un metodo para el tratamiento de una indicacion mediada por una proteina celular rho-gtpasa |
| EP2180895A4 (de) * | 2007-08-30 | 2012-04-11 | Prelief Inc | Verfahren zur verbesserten heilung einer mundverletzung mithilfe von glycerophosphatsalz |
| EP2203152A4 (de) | 2007-10-03 | 2011-05-25 | Myrex Pharmaceuticals Inc | Mundspülung und verfahren zu ihrer anwendung zur behandlung von mucositis oder stomatitis |
| WO2009114325A2 (en) | 2008-03-03 | 2009-09-17 | Tosk, Incorporated | Methotrexate adjuvants to reduce toxicity and methods for using the same |
| EP2418945B1 (de) | 2009-04-15 | 2018-12-05 | BMG PHARMA S.p.A. | Mineralsalz-schwefelsäure-zusammensetzungen und verfahren zu ihrer verwendung |
| EP2801348B1 (de) * | 2011-12-16 | 2019-05-22 | Hayashibara Co., Ltd. | Orale waschzusammensetzung zur vorbeugung und/oder behandlung von periodontopathien |
| US11103546B2 (en) | 2014-01-29 | 2021-08-31 | Vita Ice Therapeutics Llc | Edible oil compositions to treat oral complications and methods of using same |
| HUE057052T2 (hu) * | 2016-02-18 | 2022-04-28 | Invirsa Inc | 5'-adenozin-difoszfát-ribóz (ADPR) gyógyászati alkalmazása |
| WO2019191026A2 (en) * | 2018-03-27 | 2019-10-03 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
| EP3836942A4 (de) | 2018-08-14 | 2022-05-18 | Tosk, Inc. | Verfahren und zusammensetzungen zur verminderung der strahlungsinduzierten toxizität |
| EP3836941A4 (de) | 2018-08-14 | 2022-05-18 | Tosk, Inc. | Verfahren und zusammensetzungen zur behandlung von mukositis |
| WO2020036975A1 (en) | 2018-08-14 | 2020-02-20 | Tosk, Inc. | Methods and compositions for reducing fluorouracil induced toxicity |
| CN112839662A (zh) * | 2018-10-17 | 2021-05-25 | 莱克伍德阿美达克斯股份有限公司 | 用于治疗口腔粘膜炎的方法和组合物 |
| US11446303B2 (en) | 2019-06-21 | 2022-09-20 | Tosk, Inc. | Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions |
| WO2022010778A1 (en) | 2020-07-07 | 2022-01-13 | Tosk, Inc. | Uridine phosphorylase inhibitors to treat or prevent pulmonary disease |
| KR102789553B1 (ko) | 2021-09-07 | 2025-04-03 | 주식회사 펄스인마이어스 | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4118672A (en) * | 1976-07-28 | 1978-10-03 | Nippon Electric Company, Ltd. | Attenuation equalizer having constant resistance |
| US5118672A (en) * | 1989-07-10 | 1992-06-02 | University Of Georgia Research Foundation | 5'-diphosphohexose nucleoside pharmaceutical compositions |
| US5817625A (en) * | 1992-09-21 | 1998-10-06 | Oncogene Science, Inc. | Methods of prevention of oral mucositis with transforming growth factor beta |
| JPH07247210A (ja) * | 1994-03-09 | 1995-09-26 | Sunstar Inc | 口腔用組成物 |
| US5656284A (en) * | 1995-04-24 | 1997-08-12 | Balkin; Michael S. | Oral transmucosal delivery tablet and method of making it |
| US5801159A (en) * | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| US5942243A (en) * | 1996-11-12 | 1999-08-24 | Polytherapeutics, Inc. | Mucoadhesive compositions for administration of biologically active agents to animal tissue |
| CA2302687A1 (en) * | 1997-09-11 | 1999-03-18 | Oxigene, Inc. | Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases |
| US6197334B1 (en) * | 1998-04-13 | 2001-03-06 | Donald V. Renda | Lozenge and method of making |
| US6624150B2 (en) * | 1999-02-26 | 2003-09-23 | Inspire Pharmaceuticals, Inc. | Method of treating gastrointestinal tract disease with purinergic receptor agonists |
| US6528042B1 (en) * | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| EP1370139A4 (de) * | 2001-01-04 | 2010-09-22 | Einstein Coll Med | Inhibitoren von adp-ribosyltransferasen, -cyclasen und -hydrolasen und deren verwendung |
-
2003
- 2003-04-18 US US10/419,007 patent/US20030236217A1/en not_active Abandoned
- 2003-04-18 WO PCT/US2003/011840 patent/WO2003099297A1/en not_active Ceased
- 2003-04-18 AU AU2003230952A patent/AU2003230952A1/en not_active Abandoned
- 2003-04-18 AT AT03724064T patent/ATE417616T1/de not_active IP Right Cessation
- 2003-04-18 EP EP03724064A patent/EP1509234B1/de not_active Expired - Lifetime
- 2003-04-18 DE DE60325353T patent/DE60325353D1/de not_active Expired - Lifetime
- 2003-05-02 TW TW092112205A patent/TW200402301A/zh unknown
- 2003-05-20 AR ARP030101748A patent/AR040036A1/es unknown
-
2005
- 2005-12-27 US US11/318,677 patent/US20060105985A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/931,613 patent/US20080081796A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20030236217A1 (en) | 2003-12-25 |
| HK1074784A1 (en) | 2005-11-25 |
| US20080081796A1 (en) | 2008-04-03 |
| DE60325353D1 (de) | 2009-01-29 |
| TW200402301A (en) | 2004-02-16 |
| AU2003230952A1 (en) | 2003-12-12 |
| EP1509234B1 (de) | 2008-12-17 |
| US20060105985A1 (en) | 2006-05-18 |
| AR040036A1 (es) | 2005-03-09 |
| WO2003099297A1 (en) | 2003-12-04 |
| EP1509234A1 (de) | 2005-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1622633A4 (de) | Behandlung von t-zell-vermittelten krankheiten | |
| DE60325353D1 (de) | Behandlung von mukositis | |
| ATE512163T1 (de) | Verabreichung von mitteln zur behandlung von entzündungen | |
| DE69925306D1 (de) | Behandlung von kohlenwasserstoffgas | |
| DE50214540D1 (de) | Stanz bei der behandlung von wunden | |
| ATE323661T1 (de) | Behandlung von mineralischen stoffen | |
| DE60322582D1 (de) | Oberflächenbehandlung von medizinischem gerät | |
| DE60325498D1 (de) | 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen | |
| EP1742675A4 (de) | Behandlung von biomedizinischem abfall | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| EP1485109A4 (de) | Gefässtherapeutika | |
| EP1117431A4 (de) | Behandlung von acidose | |
| ATE254913T1 (de) | Diacerein zur behandlung von psoriasis | |
| DE602004022035D1 (de) | Verwendung von pthalide derivativen zur behandlung | |
| DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
| DE602004004262D1 (de) | Ultraschallbehandlung von gewebematrices | |
| ATE369136T1 (de) | Therapeutische behandlung | |
| ATE273276T1 (de) | Cyclobutendion-derivate zur behandlung von artherosclerose | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| DE60103685D1 (de) | Behandlung von Poriomania | |
| DE60110748D1 (de) | Behandlung von fluorkohlenstoff-beschickungen | |
| DE602004026773D1 (de) | Verfahrensherstellung von ethern | |
| DE60223707D1 (de) | Calcium-l-threonat zur behandlung von knochenfrakturen | |
| DE60026821D1 (de) | Behandlung von bohrspülung | |
| ATE526970T1 (de) | Behandlung von mastitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |